Get the Stockscreener App
11.78
8.96%
-1.16
Forte Biosciences Inc stock is traded at $11.78, with a volume of 61,412.
It is down -8.96% in the last 24 hours and down -23.95% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
See More
Previous Close:
$12.94
Open:
$12.94
24h Volume:
61,412
Relative Volume:
0.69
Market Cap:
$146.46M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-11.33
EPS:
-1.04
Net Cash Flow:
$-28.71M
1W Performance:
-9.38%
1M Performance:
-23.95%
6M Performance:
+69.25%
1Y Performance:
+181.82%
1-Day Range:
$11.58
$13.46
1-Week Range:
$11.58
$15.10
52-Week Range:
$4.12
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
11.78 | 160.88M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Initiated | Guggenheim | Buy |
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Why Forte Biosciences Inc. stock is in analyst buy zone2025 Price Targets & Long Hold Capital Preservation Tips - newser.com
How Forte Biosciences Inc. stock reacts to Fed rate cutsMarket Volume Report & Safe Swing Trade Setups - newser.com
Forte Biosciences, Inc. (NASDAQ:FBRX) Sees Significant Growth in Short Interest - MarketBeat
Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences - Bluefield Daily Telegraph
Forte Bio (NASDAQ: FBRX) to present at Guggenheim, TD Cowen, Evercore in Nov-Dec - Stock Titan
How Forte Biosciences Inc. stock performs after earningsJuly 2025 Selloffs & Weekly Watchlist for Consistent Profits - newser.com
Why Forte Biosciences Inc. stock appeals to analystsSell Signal & Precise Swing Trade Entry Alerts - newser.com
Signal strength of Forte Biosciences Inc. stock in tech scannersJuly 2025 Drop Watch & Weekly Watchlist for Consistent Profits - newser.com
Is Forte Biosciences Inc. stock affected by interest rate hikes2025 Technical Overview & High Accuracy Trade Alerts - newser.com
Detecting support and resistance levels for Forte Biosciences Inc.Jobs Report & Expert Curated Trade Setups - newser.com
News impact scoring models applied to Forte Biosciences Inc.Quarterly Performance Summary & Technical Entry and Exit Tips - newser.com
Forte Biosciences, Inc. $FBRX Stake Boosted by AlphaQuest LLC - Defense World
What analyst consensus implies for Forte Biosciences Inc. (37T) stockPortfolio Risk Summary & Reliable Entry Point Trade Alerts - newser.com
Why Forte Biosciences Inc. (37T) stock appeals to dividend investorsPortfolio Return Report & Entry and Exit Point Strategies - newser.com
How strong is Forte Biosciences Inc. stock balance sheetGlobal Markets & AI Enhanced Trading Alerts - newser.com
How Forte Biosciences Inc. stock performs in interest rate cyclesWeekly Trading Summary & Risk Controlled Stock Pick Alerts - newser.com
How to interpret RSI for Forte Biosciences Inc. stockJuly 2025 Breakouts & Free Verified High Yield Trade Plans - newser.com
Smart tools for monitoring Forte Biosciences Inc.’s price action2025 Growth vs Value & AI Based Buy/Sell Signal Reports - newser.com
Forte Biosciences (NASDAQ:FBRX) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
What analysts say about Forte Biosciences Inc stockMarket Volatility Update & Free High Impact Stock Picks - earlytimes.in
Weiss Ratings Reaffirms "Sell (E+)" Rating for Forte Biosciences (NASDAQ:FBRX) - MarketBeat
How Forte Biosciences Inc. stock performs in rate cut cycles2025 Price Targets & Long-Term Investment Growth Plans - newser.com
Investors Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - MarketBeat
Will Forte Biosciences Inc. stock outperform growth indexesPortfolio Gains Report & Consistent Income Trade Ideas - newser.com
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):